Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Why Aspen Stock Is Plunging Today

Aspen Technology, Inc (NASDAQ: AZPN) is trading lower Thursday since its third-quarter earnings miss.
byAnusuya Lahiri
April 27, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • Aspen Technology, Inc (NASDAQ:AZPN) is trading lower Thursday since its third-quarter earnings miss.
  • On Wednesday after-hours, Aspen Tech reported 172% revenue growth year-on-year to $229.88 million, missing the consensus of $285.64 million.
  • Adjusted EPS of $1.06 missed the consensus of $1.74.
  • The annual contract value was $854.6 million, up 11.2% Y/Y.
  • Annual spending for heritage AspenTech, was $712.0 million, up by 8.6% Y/Y.
  • License and solutions revenue grew to $136.3 million, up from $50.8 million a year ago. Maintenance revenue was $77.3 million, up from $27.3 million a year earlier. Services and other revenue grew to $16.3 million compared to $6.5 million a year ago.
  • AspenTech reported a loss from operations of $(78.5) million, compared to a loss of $(2.7) million a year ago.
  • Outlook: Aspen Tech expects FY23 revenue of $1.04 billion – $1.06 billion (consensus $1.17 billion) and adjusted EPS of $5.63 – $5.83 (consensus $7.06).
  • Analyst Ratings: Keybanc analyst Jason Celino maintains Aspen Tech with an Overweight, lowering the price target from $260 to $230.
  • Piper Sandler analyst Clarke Jeffries reiterates a Neutral and maintains a $195 price target.
  • William Blair analyst Matthew Pfau downgrades from Outperform to Market Perform.
  • Loop Capital analyst Mark Schappel maintains a Buy and lowers the price target from $270 to $240.
  • Price Action: AZPN shares traded lower by 25.9% at $171.70 on the last check Thursday.
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

What’s Going On With Marijuana-Producer Tilray Stock?

By Erica Kollmann
January 16, 3:22 PM
The 252 pages of documents confirm that the Department of Health and Human Services has recommended the DEA reschedule cannabis as Schedule III under the Controlled Substances Act. The documents explain that cannabis "has a currently accepted medical use in treatment in the United States" and that it has a "potential for abuse less than the drugs or other substances in Schedules I and II," as first reported by Marijuana Moment. 

TLRY